FINHUB Insights

Baxter International

BAX · Health Care · Market cap $14.3B

  1. Q2 FY25 Apr–Jun 2025
  2. Q3 FY25 Jul–Sep 2025
  3. Q4 FY25 Oct–Dec 2025
  4. Q1 FY26 Mar 2026

Q1 FY26 Mar 31, 2026 reported Apr 30, 2026

Revenue$2.7B +3% year over year
Gross profit$0.9B
Operating profit$0.1B
Net profit$0B -1% margin
Sankey diagram of Baxter International's income statement for Q1 FY26
Numbers and detail
All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 2.7 100% +3%
Medical Products & Therapies 1.3 48%
Healthcare Systems & Technologies 0.7 26%
Pharmaceuticals 0.6 22% +7%
Other 0.1 4% +15%
Cost of revenue−1.867%
Gross profit0.933% margin+0pp
Research & development−0.15%+0pp
SG&A−0.727%+0pp
Operating profit0.12% margin+0pp
Interest & other costs−0.1
Net profit0-1%−5pp

Filing on EDGAR · This quarter on its own page

Quarter by quarter

Pick a quarter and the diagram above changes. Bars compare revenue across the quarters we hold.

Quarter Period Reported Revenue Year over year Operating margin Net profit Net margin
Q1 FY26 Mar 31, 2026 Apr 30, 2026 $2.7B +3% 4% $0B -1%
Q4 FY25 Oct 1 – Dec 31, 2025 Feb 12, 2026 $3B +8% -23% $-1.1B -38%
Q3 FY25 Jul 1 – Sep 30, 2025 Nov 4, 2025 $2.8B +5% 7% $0B -2%
Q2 FY25 Apr 1 – Jun 30, 2025 Aug 5, 2025 $2.8B +4% 7% $0.1B 3%